

Infraredx Announces Executive Leadership Change

Jason Bottiglieri Steps Down as Infraredx President and CEO

BURLINGTON, Mass., December 14, 2018 -- Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, has announced today that Jason Bottiglieri has formally resigned from his four-year post as President and Chief Executive Officer, effective December 14, 2018, to pursue other leadership opportunities outside of Infraredx.

Since 2011, Mr. Bottiglieri has played a critical role in the development, growth and success of Infraredx, a Nipro Company. While he will be missed in his leadership role, we wish him the best of luck in his new endeavor.

“Infraredx is entering a very exciting period in its history, which has made this decision to move on to other opportunities even more difficult,” said Mr. Bottiglieri. “I want to thank Nipro and the Board of Directors for allowing me the privilege to serve this extraordinary company and its employees. I also want to thank our community of physicians and employees whose research, dedication and appetite for success has helped fuel the company’s growth and advancement.”

In response to Mr. Bottiglieri’s departure, Nipro Corporation and its Board of Directors, has appointed Nozomu Fujita as the President and Chief Executive Officer of Infraredx.

Kenji Nawa, Chairman of the Board, commented, “On behalf of the Board, I would like to personally thank Jason for his service to Infraredx. With his determination and leadership, we have successfully positioned Infraredx as a key player in the coronary imaging market and built a strong foundation for its continued growth and success.”

Mr. Nawa continued, “We are delighted to welcome our new President and CEO who will lead Infraredx through the next phase of growth, including an exciting expansion of corporate headquarters in March 2019, and continuing the R&D efforts of the Makoto[™] Intravascular Imaging System. Nipro remains committed to the success of Infraredx and the role it plays in the coronary imaging market. Mr. Fujita, together with the dedicated and experienced executive management team, will work diligently to make certain this leadership transition is seamless for both our customers and our employees.”

Mr. Fujita been employed at Nipro for 24 years and served in various advancing roles in marketing, business development and sales expansion. He has most recently served as Infraredx’s Director of Marketing, Asia Pacific, and played a critical role during Nipro Corporation’s acquisition of Infraredx in 2015. During that time, Mr. Fujita has worked to penetrate the Japanese IVUS market with the Makoto[™] Intravascular Imaging System and acted as a liaison for business development between the Infraredx and Nipro management teams. During his time at Nipro, he has been involved in all aspects of business development surrounding the vascular market, global development and expansion of various medical devices to the global market.

“I am excited to be offered this opportunity to lead Infraredx at such an important time in its history,” said Mr. Fujita. “With positive LRP results, and the expansion of R&D efforts to a new facility, this is an exciting time. I look forward to working with this talented, professional and passionate team to continue its success and create a seamless transition for our customers.”

The company recently launched the Makoto™ Intravascular Imaging System, and accompanying Dualpro™ IVUS+NIRS catheter in Japan, the world’s largest imaging market. The launch followed a successful Spring 2018 limited market release, which included more than 10 hospitals in Japan. Infraredx plans for to launch the product in the U.S. in early 2019. In addition, Infraredx will move all employees to a new 40,000 sq. feet corporate headquarters in Bedford, Mass., in April 2019, to make room for the expansion of the manufacturing and R&D efforts of the Makoto™ Imaging System and Dualpro™ IVUS+NIRS Catheter.

About Infraredx, Inc.

Infraredx, Inc., a Nipro company, is advancing the diagnosis and management of coronary artery disease by providing cardiologists with the most precise imaging tools required to predict and ultimately prevent heart attacks. Its Makoto™ Intravascular Imaging System, with accompanying Dualpro™ IVUS+NIRS catheter, is the only technology on the market that is FDA-cleared for the detection of lipid core plaque (LCP). LCP, suspected to be vulnerable plaque, is well-documented in studies as the cause of most serious heart attacks. Infraredx is dedicated to advancing this important field of research and conducting landmark clinical trials to transform how we view and treat heart disease. For more information, please visit www.infraredx.com and connect with Infraredx on [Twitter](#) and [LinkedIn](#).

###

Contact:

Kaitlyn Dmyterko
Marketing Communications Manager
Infraredx, a Nipro Company
781-345-9634
kdmyterko@infraredx.com